- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT05714085
Effekt, sikkerhed og farmakokinetik af Vericiguat hos pædiatriske deltagere med hjertesvigt på grund af venstre ventrikulær systolisk dysfunktion (MK-1242-036)
Et fase 2/3 randomiseret, placebokontrolleret, dobbeltblindt, klinisk studie til evaluering af Vericiguats effektivitet, sikkerhed og farmakokinetik hos pædiatriske deltagere med hjertesvigt på grund af systemisk venstre ventrikulær systolisk dysfunktion (VALOR)
This study aims to compare the efficacy of vericiguat versus placebo on change in n-terminal pro-brain natriuretic peptide (NTproBNP) from baseline to Week 16 of the Base Period. The primary hypothesis is that vericiguat is superior to placebo in reducing NT-proBNP at Week 16 of the Base Period.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
As of Protocol Amendment 2, the separate open-label extension arm of study MK-1242-043 (NCT06428383) will be incorporated into the present MK-1242-036 study as an extension period. Participants from the Base Period will be provided the opportunity to participate in the optional open-label Extension Period if eligible. After all ongoing participants are transferred into the extension period of MK-1242-036, MK-1242-043 (NCT06428383) will be formally closed.
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 2
- Fase 3
Kontakter og lokationer
Studiekontakt
- Navn: Toll Free Number
- Telefonnummer: 1-888-577-8839
- E-mail: Trialsites@msd.com
Studiesteder
-
-
Liege
-
Liège, Liege, Belgien, 4000
- Afsluttet
- Centre Hospitalier Régional de la Citadelle ( Site 0302)
-
-
Oost-Vlaanderen
-
Ghent, Oost-Vlaanderen, Belgien, 9000
- Rekruttering
- UZ Gent ( Site 0301)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +32 9 332 24 30
-
-
Vlaams-Brabant
-
Leuven, Vlaams-Brabant, Belgien, 3000
- Rekruttering
- UZ Leuven ( Site 0300)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +32 16 34 59 98
-
-
-
-
-
São Paulo, Brasilien, 05403-900
- Rekruttering
- Incor - Instituto do Coracao ( Site 0400)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +55 11 2661 5450
-
-
São Paulo
-
São Paulo, São Paulo, Brasilien, 04012-909
- Rekruttering
- Instituto Dante Pazzanese de Cardiology ( Site 0402)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 55 11 5085 6866
-
-
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 2B7
- Rekruttering
- Stollery Children's Hospital ( Site 0501)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 780-407-1586
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 1X8
- Rekruttering
- The Hospital for Sick Children ( Site 0500)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 416-813-1500
-
-
Quebec
-
Sherbrooke, Quebec, Canada, J1H 5H4
- Rekruttering
- Centre intégré universitaire de santé et de services sociaux-Centre de recherche du CHUS ( Site 0502)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 819-346-1110, 12889
-
-
-
-
Antioquia
-
Rionegro, Antioquia, Colombia, 054040
- Rekruttering
- Clinica Somer ( Site 0607)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 57 3125891661
-
-
Atlántico
-
Barranquilla, Atlántico, Colombia, 08001
- Rekruttering
- Ciensalud Ips S A S ( Site 0608)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +573506961481
-
-
Bogota D.C.
-
Bogotá, Bogota D.C., Colombia, 110131
- Rekruttering
- Fundación Cardioinfantil Instituto de Cardiología ( Site 0603)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 6017563426 EXT 73205
-
-
Valle del Cauca Department
-
Cali, Valle del Cauca Department, Colombia, 760032
- Rekruttering
- Fundación Valle del Lili ( Site 0604)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +573133288646
-
Cali, Valle del Cauca Department, Colombia, 760042
- Rekruttering
- Clínica Imbanaco S.A.S ( Site 0602)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +573117441693
-
-
-
-
Capital Region
-
Copenhagen, Capital Region, Danmark, DK-2100
- Rekruttering
- Rigshospitalet-BørneUngeAfdelingen ( Site 0800)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +45 35453545
-
-
-
-
-
Newcastle upon Tyne, Det Forenede Kongerige, NE7 7DN
- Rekruttering
- Freeman Hospital ( Site 3400)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 07899895040
-
-
London, City of
-
London, London, City of, Det Forenede Kongerige, WC1N 3JH
- Rekruttering
- Great Ormond Street Hospital For Children NHS Foundation Trust ( Site 3401)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 020 7405 9200
-
-
-
-
Pirkanmaa
-
Tampere, Pirkanmaa, Finland, 33520
- Rekruttering
- Tampereen yliopistollinen sairaala-Pediatric Early Phase Trials Unit ( Site 0900)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +358503539956
-
-
-
-
California
-
Los Angeles, California, Forenede Stater, 90095
- Rekruttering
- The Regents of the University of California - Los Angeles (UCLA Pediatrics) ( Site 0002)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 310-825-9111
-
Palo Alto, California, Forenede Stater, 94304
- Rekruttering
- Lucile Packard Children's Hospital ( Site 0040)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 650-721-2121
-
San Bernardino, California, Forenede Stater, 92408
- Rekruttering
- Loma Linda University Health System ( Site 0008)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 909-558-5830
-
-
Colorado
-
Aurora, Colorado, Forenede Stater, 80045
- Afsluttet
- Children's Hospital Colorado ( Site 0012)
-
-
District of Columbia
-
Washington D.C., District of Columbia, Forenede Stater, 20010
- Rekruttering
- Children's National Medical Center ( Site 0020)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 888-884-2327
-
-
Florida
-
St. Petersburg, Florida, Forenede Stater, 33701
- Rekruttering
- Johns Hopkins All Children's Hospital ( Site 0029)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 727-898-7451
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30329
- Rekruttering
- Children's Healthcare of Atlanta - Arthur M. Blank Hospital ( Site 0001)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 404-785-0381
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02115
- Rekruttering
- Boston Children's Hospital ( Site 0035)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 617-355-4213
-
-
Michigan
-
Ann Arbor, Michigan, Forenede Stater, 48109
- Rekruttering
- C.S. Mott Children's Hospital ( Site 0033)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 734-615-0590
-
-
Missouri
-
St Louis, Missouri, Forenede Stater, 63110
- Rekruttering
- Washington University-Pediatric Cardiology/ St. Louis Children's Hospital ( Site 0006)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 800-678-4357
-
-
New York
-
New York, New York, Forenede Stater, 10032
- Rekruttering
- Columbia University Medical Center-Pediatric Cardiology ( Site 0016)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 212-305-5437
-
The Bronx, New York, Forenede Stater, 10467
- Rekruttering
- The Children's Hospital at Montefiore ( Site 0030)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 718-741-2426
-
-
Ohio
-
Cincinnati, Ohio, Forenede Stater, 45229
- Rekruttering
- Cincinnati Children's Hospital Medical Center ( Site 0034)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 513-636-3016
-
Cleveland, Ohio, Forenede Stater, 44195
- Rekruttering
- Cleveland Clinic-Cleveland Clinic Chidren's ( Site 0022)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 216-444-2200
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forenede Stater, 19104
- Rekruttering
- Children's Hospital of Philadelphia (CHOP) ( Site 0004)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 215-590-1000
-
Pittsburgh, Pennsylvania, Forenede Stater, 15224
- Rekruttering
- Children's Hospital of Pittsburgh ( Site 0010)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 412-692-5325
-
-
Tennessee
-
Memphis, Tennessee, Forenede Stater, 38103
- Rekruttering
- Le Bonheur Children's Hospital ( Site 0007)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 901-287-5760
-
-
Texas
-
Dallas, Texas, Forenede Stater, 75235
- Rekruttering
- Children's Health-The Heart Center ( Site 0015)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 214-456-7000
-
Houston, Texas, Forenede Stater, 77030
- Rekruttering
- Texas Children's Hospital ( Site 0039)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 832-826-2806
-
-
Washington
-
Seattle, Washington, Forenede Stater, 98105
- Rekruttering
- Seattle Children's Hospital-Cardiology/Fetal Therapy ( Site 0019)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 206-987-2015
-
-
-
-
-
Paris, Frankrig, 75019
- Afsluttet
- Assistance Publique - Hopitaux de Paris (AP-HP) - Hopital Robert Debre - Centre Hospitalo Universita ( Site 1004)
-
Paris, Frankrig, 75015
- Afsluttet
- Hôpital Universitaire Necker Enfants Malades ( Site 1001)
-
-
Aquitaine
-
Pessac, Aquitaine, Frankrig, 33600
- Afsluttet
- CHU Bordeaux Haut-Leveque ( Site 1000)
-
-
Loire-Atlantique
-
Nantes, Loire-Atlantique, Frankrig, 44093
- Afsluttet
- Centre Hospitalier Universitaire de Nantes - Hôpital Femme-Enfant-Adolescent Chu De Nantes ( Site 1002)
-
-
Nord
-
Lille, Nord, Frankrig, 59037
- Afsluttet
- CHU Lille - Institut Coeur Poumon ( Site 1005)
-
-
Provence-Alpes-Côte d'Azur Region
-
Marseille, Provence-Alpes-Côte d'Azur Region, Frankrig, 13005
- Afsluttet
- Assistance Publique Hôpitaux de Marseille - Hôpital de la Timone ( Site 1003)
-
-
-
-
-
Groningen, Holland, 9713 GZ
- Rekruttering
- University Medical Center Groningen ( Site 1901)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 31503612800
-
Utrecht, Holland, 3584 CX
- Rekruttering
- Universitair Medisch Centrum Utrecht ( Site 1902)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 31 88 75 547
-
-
South Holland
-
Rotterdam, South Holland, Holland, 3015 CN
- Rekruttering
- Erasmus Medisch Centrum ( Site 1900)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 0031650162663
-
-
-
-
-
Dublin, Irland, D12 N512
- Rekruttering
- Children's Health Ireland (CHI) at Crumlin ( Site 1400)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 01-4282854
-
-
-
-
Liguria
-
Genoa, Liguria, Italien, 16147
- Rekruttering
- IRCCS Istituto Giannina Gaslini ( Site 1603)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +3901056363993
-
-
Lombardy
-
Milan, Lombardy, Italien, 20154
- Rekruttering
- Ospedale dei Bambini "Vittore Buzzi" ( Site 1606)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +390263635733
-
-
Piedmont
-
Turin, Piedmont, Italien, 10126
- Rekruttering
- Ospedale Infantile Regina Margherita ( Site 1604)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +390113131853
-
-
Roma
-
Rome, Roma, Italien, 00165
- Rekruttering
- Ospedale Pediatrico Bambino Gesù IRCCS ( Site 1602)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +390668592217
-
-
Tuscany
-
Florence, Tuscany, Italien, 50139
- Afsluttet
- A.O.Universitaria Meyer ( Site 1600)
-
-
Veneto
-
Padova, Veneto, Italien, 35128
- Rekruttering
- Azienda Ospedale - Università Padova ( Site 1601)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 0498213558
-
-
-
-
City of Zagreb
-
Zagreb, City of Zagreb, Kroatien, 10000
- Rekruttering
- Klinički bolnički centar Zagreb ( Site 3700)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 0038512367590
-
-
-
-
-
Kuala Lumpur, Malaysia, 50400
- Rekruttering
- Institut Jantung Negara ( Site 1705)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 603-26178465
-
Kuala Lumpur, Malaysia, 50300
- Rekruttering
- Hospital Tunku Azizah-Paediatric ( Site 1700)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +60326003000
-
-
Kelantan
-
Kota Bharu, Kelantan, Malaysia, 16150
- Rekruttering
- Hospital Pakar Universiti Sains Malaysia ( Site 1703)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +6097673000
-
-
Kuala Lumpur
-
Lembah Pantai, Kuala Lumpur, Malaysia, 59100
- Rekruttering
- University Malaya Medical Centre ( Site 1701)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +60479492351
-
-
Sabah
-
Kota Kinabalu, Sabah, Malaysia, Kota Kinab
- Rekruttering
- Hospital Queen Elizabeth II ( Site 1706)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +6088324600
-
-
-
-
-
Aguascalientes, Mexico, 20129
- Rekruttering
- Centro de Atención e Investigación Clínica ( Site 1813)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +525543673716
-
Colima, Mexico, 28000
- Rekruttering
- UROLAP ( Site 1812)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +523121552653
-
México, Mexico, 14080
- Rekruttering
- Instituto Nacional de Cardiologia Ignacio Chavez ( Site 1804)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +525520917905
-
-
Guanajuato
-
León, Guanajuato, Mexico, 37000
- Rekruttering
- Morales Vargas Centro de Investigacion S. C. ( Site 1810)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +524777160714
-
-
Jalisco
-
Guadalajara, Jalisco, Mexico, 44690
- Rekruttering
- CINVEC Medica ( Site 1814)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +523338012160
-
-
Mexico City
-
Mexico City, Mexico City, Mexico, 04530
- Rekruttering
- Instituto Nacional de Pediatria ( Site 1803)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +525556069738
-
-
Nuevo León
-
Monterrey, Nuevo León, Mexico, 66460
- Rekruttering
- Hospital Universitario "Dr. Jose Eleuterio Gonzalez"-Pediatria ( Site 1816)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +528183486173
-
-
State of Mexico
-
Hacienda de Las Palmas, State of Mexico, Mexico, 52763
- Rekruttering
- INVECORDIS S.C. ( Site 1808)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 5552469710
-
-
Tamaulipas
-
Ciudad Madero, Tamaulipas, Mexico, 89440
- Rekruttering
- Centro de Estudios de Investigacion Metabolicos y Cardiovasculares ( Site 1800)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +528331260055
-
-
-
-
-
Auckland, New Zealand, 1023
- Rekruttering
- Auckland City Hospital ( Site 2000)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +6493670009
-
-
-
-
Lima
-
Jesús María, Lima, Peru, 15072
- Afsluttet
- Instituto Nacional Cardiovascular INCOR Carlos Peschiera Carrillo - EsSalud ( Site 2100)
-
-
Lima region
-
San Borja, Lima region, Peru, 15037
- Rekruttering
- Instituto Nacional de Salud del Nino San Borja ( Site 2105)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +512300600
-
-
-
-
Pomeranian Voivodeship
-
Gdansk, Pomeranian Voivodeship, Polen, 80-952
- Afsluttet
- Uniwersyteckie Centrum Kliniczne-Klinika Kardiologii Dziecięcej i Wad Wrodzonych Serca ( Site 2302)
-
-
-
-
-
Lisbon, Portugal, 1649-035
- Afsluttet
- Unidade Local de Saude de Santa Maria - Hospital de Santa Maria ( Site 2402)
-
Porto, Portugal, 4200-319
- Aktiv, ikke rekrutterende
- Unidade Local de Saúde de São João ( Site 2403)
-
-
Lisbon District
-
Lisbon, Lisbon District, Portugal, 2790-134
- Afsluttet
- Unidade Local de Saude Lisboa Ocidental - Hospital de Santa Cruz ( Site 2401)
-
-
-
-
Makkah Al Mukarramah
-
Jeddah, Makkah Al Mukarramah, Saudi Arabien, 23433
- Rekruttering
- King Faisal Specialist Hospital ( Site 4130)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +966533842107
-
-
Riyadh Region
-
Al Ahsa, Riyadh Region, Saudi Arabien, 31982
- Rekruttering
- King Abdullah International Medical Research Center ( Site 4145)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +966506920153
-
Riyadh, Riyadh Region, Saudi Arabien, 12713
- Rekruttering
- King Faisal Specialist Hospital and Research Center ( Site 4100)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +966114647272
-
Riyadh, Riyadh Region, Saudi Arabien, 11426
- Rekruttering
- King Abdul Aziz Medical City - AlRiyadh ( Site 4110)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +966112520088
-
-
-
-
Beograd
-
Belgrade, Beograd, Serbien, 11000
- Rekruttering
- Childrens University Hospital ( Site 4200)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +381641212915
-
Belgrade, Beograd, Serbien, 11000
- Rekruttering
- Institut za zdravstvenu zastitu majke i deteta Srbije ( Site 4220)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +381658405885
-
-
Vojvodina
-
Novi Sad, Vojvodina, Serbien, 21000
- Rekruttering
- Institute for Child and Youth Helth Care of Vojvodina ( Site 4210)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +381642115233
-
-
-
-
South West
-
Singapore, South West, Singapore, 119074
- Rekruttering
- National University Hospital-Paediatrics ( Site 2600)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 67795555
-
Singapore, South West, Singapore, 229899
- Rekruttering
- KK Women's and Children's Hospital ( Site 2601)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 63941960
-
-
-
-
-
Madrid, Spanien, 28046
- Rekruttering
- Hospital Universitario La Paz ( Site 2912)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +34638372829
-
Seville, Spanien, 41013
- Afsluttet
- HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO ( Site 2907)
-
-
Barcelona
-
Esplugues de Llobregat, Barcelona, Spanien, 08950
- Rekruttering
- Hospital Sant Joan de Déu-Pediatric cardiology ( Site 2902)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +34 932532100
-
-
Catalonia
-
Barcelona, Catalonia, Spanien, 08035
- Rekruttering
- Hospital Universitari Vall d'Hebron ( Site 2903)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 934893135
-
-
La Coruna
-
A Coruña, La Coruna, Spanien, 15009
- Rekruttering
- Hospital Materno-Infantil Teresa Herrera ( Site 2905)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 0034689979147
-
-
Madrid, Comunidad de
-
Madrid, Madrid, Comunidad de, Spanien, 28007
- Rekruttering
- HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑON ( Site 2904)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +34915290523
-
-
-
-
Skåne County
-
Lund, Skåne County, Sverige, 22185
- Rekruttering
- Skånes Universitetssjukhus Lund ( Site 3000)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +4646171000
-
-
Stockholm County
-
Solna, Stockholm County, Sverige, 171 64
- Rekruttering
- Astrid Lindgrens Barnsjukhus ( Site 3001)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +46812373124
-
-
-
-
Western Cape
-
Cape Town, Western Cape, Sydafrika, 7700
- Rekruttering
- Children's Heart Disease Research Unit ( Site 2704)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 076 844 4074.
-
Cape Town, Western Cape, Sydafrika, 7500
- Afsluttet
- TREAD Research ( Site 2700)
-
-
-
-
-
Seoul, Sydkorea, 03080
- Rekruttering
- Seoul National University Hospital ( Site 2803)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 82220720266
-
Seoul, Sydkorea, 03722
- Rekruttering
- Severance Hospital, Yonsei University Health System ( Site 2800)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 82222288470
-
Seoul, Sydkorea, 06351
- Rekruttering
- Samsung Medical Center ( Site 2801)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +82234103538
-
-
Kyongsangnam-do
-
Pusan, Kyongsangnam-do, Sydkorea, 50612
- Afsluttet
- Pusan National University Yangsan Hospital ( Site 2802)
-
-
-
-
-
Chiang Mai, Thailand, 50200
- Rekruttering
- Maharaj Nakorn Chiang Mai Hospital-Department of Pediatrics ( Site 3201)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +66834739974
-
-
Bangkok
-
Bangkoknoi, Bangkok, Thailand, 10700
- Rekruttering
- Faculty of Medicine Siriraj Hospital ( Site 3200)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +6624197000
-
-
Changwat Khon Kaen
-
Muang, Changwat Khon Kaen, Thailand, 40002
- Afsluttet
- Faculty of Medicine - Khon Kaen University ( Site 3202)
-
-
-
-
-
Ankara, Tyrkiet (Türkiye), 06230
- Rekruttering
- Hacettepe Universite Hastaneleri ( Site 3304)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +90 (0312) 305 25 85
-
Ankara, Tyrkiet (Türkiye), 06490
- Rekruttering
- Baskent Universitesi Ankara Hastanesi ( Site 3301)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +90 (312) 246 66 66
-
Ankara, Tyrkiet (Türkiye), 06800
- Rekruttering
- Ankara Bilkent Şehir Hastanesi. ( Site 3300)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +90 312 552 60 00
-
Istanbul, Tyrkiet (Türkiye), 34668
- Afsluttet
- Dr. Siyami Ersek Göğüs Kalp Ve Damar Cerrahisi Eğitim Ve Araştırma Hastanesi ( Site 3302)
-
Izmir, Tyrkiet (Türkiye), 35210
- Afsluttet
- S.B.Ü. DR. BEHÇET UZ ÇOCUK HASTALIKLARI VE CERRAHİSİ EĞİTİM VE ARAŞTIRMA HASTANESİ ( Site 3303)
-
-
-
-
-
Berlin, Tyskland, 13353
- Rekruttering
- Deutsches Herzzentrum Berlin ( Site 1101)
-
Kontakt:
- Study Coordinator
- Telefonnummer: + 49 30 4593 - 1000
-
-
Baden-Wurttemberg
-
Freiburg im Breisgau, Baden-Wurttemberg, Tyskland, 79106
- Rekruttering
- Universitaetsklinikum Freiburg ( Site 1102)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +4976127043230
-
Heidelberg, Baden-Wurttemberg, Tyskland, 69120
- Afsluttet
- Universitaetsklinikum Heidelberg ( Site 1100)
-
-
Bavaria
-
Erlangen, Bavaria, Tyskland, 91054
- Rekruttering
- Kinderklinik des Uni-Klinikums Erlangen ( Site 1104)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +4991318533750
-
-
Lower Saxony
-
Hanover, Lower Saxony, Tyskland, 30625
- Rekruttering
- Medizinische Hochschule Hannover ( Site 1108)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +495115320
-
-
-
-
-
Budapest, Ungarn, 1096
- Rekruttering
- Gottsegen György Országos Kardiovaszkuláris Intézet-Gyermeksziv Kozpont ( Site 1300)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +3612151220
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Has symptomatic chronic heart failure (HF) resulting from systemic left ventricular (LV) systolic dysfunction.
- Has biventricular physiology with a morphologic systemic left ventricle.
- Is currently receiving stable medical therapy for HF.
- Has left ventricular ejection fraction (LVEF) <45% assessed within 3 months before randomization.
- Is of any sex/gender, from >28 days to <18 years of age inclusive. Must weigh ≥3 kg to participate.
- Female is eligible to participate if not pregnant or breastfeeding, and at least one of the following: is not a participant of childbearing potential (POCBP); or is a POCBP who uses a highly effective contraceptive method; has a negative highly sensitive pregnancy test; abstains from breastfeeding during the study intervention period and for at least 30 days after study intervention; and their medical history; their menstrual history, and recent sexual activity has been reviewed.
- Extension Period: Was randomized, received at least 1 dose of study intervention (vericiguat or placebo), did not permanently discontinue study intervention, and completed the Week 52 visit and safety follow-up period of the Base Period
Exclusion Criteria:
- Is clinically unstable-with at least one of the following: has symptomatic hypotension or is hypotensive for age, recent use of intravenous (IV) inotrope and/or IV vasodilator, or recent IV diuretic.
- Has a known allergy or sensitivity to vericiguat, any of its constituents, or any other soluble guanylate cyclase (sGC) stimulator.
- Has a history of single ventricle heart disease or has a morphologic systemic right ventricle.
- Has undergone heart transplantation, is awaiting heart transplantation United Network for Organ Sharing (UNOS) Class 1A or equivalent, is receiving continuous IV infusion of an inotrope, or has an implanted ventricular assist device.
- Has sustained or symptomatic dysrhythmia uncontrolled with drug or device therapy.
- Has had recent cardiovascular (CV) surgical procedure or percutaneous intervention to palliate or correct congenital CV malformations.
- Has unoperated or residual hemodynamically significant congenital cardiac malformations.
- Has hypertrophic or restrictive cardiomyopathy.
- Has active myocarditis or has been recently diagnosed with presumed or definitive myocarditis.
- Has acute coronary syndrome, undergone recent coronary intervention, or indication for coronary revascularization.
- Has symptomatic carotid stenosis or other symptomatic cerebrovascular disease
- Has severe pulmonary hypertension.
- Requires continuous home oxygen for significant pulmonary disease and/or has known interstitial lung disease.
- Has severe chronic kidney disease.
- Has hepatic disorder such as hepatic encephalopathy, hepatic laboratory abnormalities or Child Pugh Class C.
- Has a gastrointestinal or biliary disorder that could impair absorption, metabolism, or excretion of medications.
- Has significant bone disease (other than osteopenia) that in the assessment of the investigator can alter bone formation
- Has concurrent or anticipated concomitant use of phosphodiesterase type 5 inhibitors or an sGC stimulator.
- Has received a COVID-19 vaccination within 1 week before randomization.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Base Period: Vericiguat
Participants in the Base Period receive 2.5 mg or 5 mg or 10 mg vericiguat administered orally once daily in tablet form for 52 weeks; or 0.2 mg/mL or 1 mg/mL vericiguat administered orally once daily in suspension form for 52 weeks. |
2.5 mg or 5 mg or 10 mg vericiguat administered orally once daily in tablet form
Andre navne:
0.2 mg/mL or 1 mg/mL vericiguat administered orally once daily in suspension form
Andre navne:
|
|
Placebo komparator: Base Period: Placebo
Participants in the Base Period receive placebo for vericiguat administered orally once daily in tablet form for 52 weeks, or administered orally once daily in suspension form for 52 weeks. |
Placebo for vericiguat administered orally once daily in tablet form
Andre navne:
Placebo for vericiguat administered orally once daily in suspension form
Andre navne:
|
|
Eksperimentel: Extension Period: Vericiguat
Participants in the Extension Period receive either 2.5 mg or 5 mg or 10 mg vericiguat administered orally once daily in tablet form; or 0.2 mg/mL or 1 mg/mL vericiguat administered orally once daily in suspension form; following completion of the Base Period. |
2.5 mg or 5 mg or 10 mg vericiguat administered orally once daily in tablet form
Andre navne:
0.2 mg/mL or 1 mg/mL vericiguat administered orally once daily in suspension form
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Base Period: Change from baseline to Week 16 in N-terminal pro-brain natriuretic peptide (NT-proBNP)
Tidsramme: Baseline and Week 16 of Base Period
|
The change from baseline to Week 16 of the Base Period in log-transformed NT-proBNP will be reported. |
Baseline and Week 16 of Base Period
|
|
Extension Period: Percentage of participants with one or more adverse events (AEs)
Tidsramme: Includes data collected up to a maximum of approximately 8 years
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants with one or more AEs in the Extension Period will be reported. |
Includes data collected up to a maximum of approximately 8 years
|
|
Extension Period: Percentage of participants who discontinued study drug due to an AE
Tidsramme: Includes data collected up to a maximum of approximately 8 years
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who discontinue study drug in the Extension Period due to an AE will be reported. |
Includes data collected up to a maximum of approximately 8 years
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Base Period: Change from baseline to Week 52 in log-transformed NT-proBNP
Tidsramme: Baseline and Week 52 of Base Period
|
The change from baseline to Week 52 of the Base Period in log-transformed NT-proBNP will be reported. |
Baseline and Week 52 of Base Period
|
|
Base Period: First event of cardiovascular (CV) death, heart failure hospitalization (HFH), or worsening of heart failure (HF) without hospitalization
Tidsramme: Up to Week 54 of Base Period
|
The time from randomization to the first event of CV death, HFH, or worsening of HF without hospitalization will be reported for the Base Period. |
Up to Week 54 of Base Period
|
|
Base Period: Percentage of participants with one or more adverse events (AEs)
Tidsramme: Up to Week 54 of Base Period
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants with one or more AEs in the Base Period will be reported. |
Up to Week 54 of Base Period
|
|
Base Period: Percentage of participants who discontinued study drug due to an AE
Tidsramme: Up to Week 52 of Base Period
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who discontinue study drug in the Base Period due to an AE will be reported. |
Up to Week 52 of Base Period
|
|
Base Period: Area under the curve from time 0-24 hours post-dose (AUC0-24) of plasma vericiguat
Tidsramme: Pre-dose, 2, 6, 16, 32 and 52 weeks post-dose (Base Period)
|
Blood samples were collected at pre-specified time points pre- and post-dose and used to estimate the area under the curve from time 0-24 hours post-dose (AUC0-24) of plasma vericiguat. |
Pre-dose, 2, 6, 16, 32 and 52 weeks post-dose (Base Period)
|
|
Base Period: Half-life (t1/2) of vericiguat in plasma
Tidsramme: Pre-dose, 2, 6, 16, 32 and 52 weeks post-dose (Base Period)
|
Blood samples were collected at pre-specified time points pre- and post-dose and used to estimate the t1/2 of vericiguat in plasma. |
Pre-dose, 2, 6, 16, 32 and 52 weeks post-dose (Base Period)
|
|
Base Period: Oral clearance (CL/F) of plasma vericiguat
Tidsramme: Pre-dose, 2, 6, 16, 32 and 52 weeks post-dose (Base Period)
|
Blood samples were collected at pre-specified time points pre- and post-dose and used to estimate the CL/F of vericiguat in plasma. |
Pre-dose, 2, 6, 16, 32 and 52 weeks post-dose (Base Period)
|
|
Extension Period: Change from extension period baseline to extension period Week 16 in NT-proBNP
Tidsramme: Extension Period Baseline (Study Week 54) and Extension Period Week 16 (Study Week 70)
|
The change from the Extension Period baseline to Week 16 of the Extension Period in log-transformed NT-proBNP will be reported. |
Extension Period Baseline (Study Week 54) and Extension Period Week 16 (Study Week 70)
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Studieleder: Medical Director, Merck Sharp & Dohme LLC
Publikationer og nyttige links
Hjælpsomme links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 1242-036
- MK-1242-036 (Anden identifikator: MSD)
- 2021-004399-33 (EudraCT nummer)
- MK-1242-043 (Anden identifikator: MSD)
- 2022-501238-52-00 (Registry Identifier: EU CT)
- U1111-1275-1768 (Registry Identifier: UTN)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .